Vital KSK Holdings, Inc. (VKSKF)
OTCMKTS
· Delayed Price · Currency is USD
8.79
0.00 (0.00%)
Jul 2, 2025, 9:30 AM EDT
Vital KSK Holdings Revenue
In the fiscal year ending March 31, 2025, Vital KSK Holdings had annual revenue of 600.37B JPY with 2.19% growth. Vital KSK Holdings had revenue of 139.69B in the quarter ending March 31, 2025, with 0.81% growth.
Revenue
600.37B JPY
Revenue Growth
+2.19%
P/S Ratio
0.10
Revenue / Employee
159.84M JPY
Employees
3,756
Market Cap
400.51M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 600.37B | 12.89B | 2.19% |
| Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
| Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
| Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
| Mar 31, 2021 | 537.03B | -25.48B | -4.53% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 84.04M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |